<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02928029</url>
  </required_header>
  <id_info>
    <org_study_id>18987</org_study_id>
    <secondary_id>2016-002438-58</secondary_id>
    <nct_id>NCT02928029</nct_id>
  </id_info>
  <brief_title>Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma</brief_title>
  <official_title>A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in 2 parts. The phase 1b part will be an international, phase
      1b, open-label, dose-escalation assessment of radium-223 dichloride administered with
      bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint
      is to determine the optimal dose of radium-223 dichloride in combination with
      bortezomib/dexamethasone for the Phase 2 portion of the study.

      The phase 2 part will be an international, phase 2, double-blind, randomized,
      placebo-controlled assessment of radium-223 dichloride versus placebo administered with
      bortezomib and dexamethasone, in subjects with relapsed multiple myeloma.

      Up to approximately 30 total subjects in all dose cohorts combined will be treated in the
      phase 1b part of the study and approximately 196 subjects will be enrolled in the phase 2
      part of the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2017</start_date>
  <completion_date type="Anticipated">April 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 24, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Joint positive adjudication of safety summary in Phase 1b by steering committee (Yes/No)</measure>
    <time_frame>At approximately 13 months</time_frame>
    <description>The Steering Committee will include multiple myeloma experts and hemato oncologists and investigators.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS) in Phase 2</measure>
    <time_frame>Up to 50 months</time_frame>
    <description>PFS defined as the time (in days) from date of randomization to disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) in Phase 1b</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>In the proportion of subjects in the analysis population who have complete response (CR), stringent complete response (sCR), very good partial response (VGPR), partial response (PR), or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in Phase 1b</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Defined as the time (in days) from the date of first response to treatment (CR, sCR, VGPR, PR) to the date of disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events in phase 2</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>AEs will be collected and recorded on an ongoing basis throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) in Phase 2</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Defined as the time (in days) from date of randomization until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Symptomatic Skeletal Event (SSE) in Phase 2</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Defined as the time (days) from the date of randomization to the date of the first on-study SSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic skeletal event free survival in Phase 2</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Defined as the time from randomization to the occurrence of 1 of the following: First on-study SSE or Death from any cause if death occurs before a documented SSE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression in Phase 2</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Defined as the occurrence of either a pain increase or an increase in pain management with respect to baseline, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response in Phase 2</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Defined as the time (in days) from the date of first response to treatment (CR, sCR, VGPR, PR) to the date of disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) in Phase 2</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>In the proportion of subjects in the analysis population who have complete response (CR), stringent complete response (sCR), very good partial response (VGPR), partial response (PR), or stable disease (SD)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Phase1, arm1: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Radium-223 dichloride; 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC (standard of care) bortezomib/dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase1, arm2: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Radium-223 dichloride; 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase1, arm3: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1: Radium-223 dichloride; 88 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses plus SOC bortezomib/dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2, arm1: Placebo+SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase 2: Matching placebo (isotonic saline) every 6 weeks for a total of 6 doses plus SOC bortezomib/dexamethasone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase2, arm2: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2: Phase 1b-selected dose of radium-223 dichloride every 6 weeks for 6 doses plus SOC bortezomib/dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride (Xofigo, BAY88-8223)</intervention_name>
    <description>Sequential dose escalation in Intravenous (IV) injection</description>
    <arm_group_label>Phase1, arm1: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase1, arm2: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase1, arm3: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase2, arm2: Radium-223 dichloride+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Phase2, arm1: Placebo+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose</description>
    <arm_group_label>Phase1, arm1: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase1, arm2: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase1, arm3: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase2, arm1: Placebo+SOC</arm_group_label>
    <arm_group_label>Phase2, arm2: Radium-223 dichloride+SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone is administered orally at 40 mg</description>
    <arm_group_label>Phase1, arm1: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase1, arm2: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase1, arm3: Radium-223 dichloride+SOC</arm_group_label>
    <arm_group_label>Phase2, arm1: Placebo+SOC</arm_group_label>
    <arm_group_label>Phase2, arm2: Radium-223 dichloride+SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have documented monoclonal plasma cells as defined by their institutional
             standard in the bone marrow &gt;=10% at some point in their disease history or presence
             of a biopsy proven plasmacytoma

          -  Subjects must have received at least 1 and not more than 3 previous lines of treatment
             and have had a response to treatment (i.e., achieved a minimal response [MR] or
             better) according to the International Myeloma Working Group (IMWG) uniform response
             criteria

          -  Subject must be non-refractory to bortezomib or another proteasome inhibitor (PI),
             like ixazomib and carfilzomib (Refractory is defined: progression of disease while
             receiving bortezomib therapy or within 60 days of ending bortezomib therapy or another
             PI therapy, like ixazomib and carfilzomib)

          -  Subjects must have had progressive disease according to the IMWG uniform response
             criteria following the last multiple myeloma treatment

          -  Subjects must have measurable disease defined as at least 1 of the following
             (according to central laboratory results):

               -  Serum M-protein ≥1 g/dL defined by the following:

                    -  IgG multiple myeloma: Serum monoclonal paraprotein (M protein) level ≥1.0
                       g/dL

                    -  IgA, IgD, IgE, IgM multiple myeloma: serum M-protein level ≥0.5 g/dL

               -  Urine M-protein ≥200 mg/24 hours (any immunoglobulin heavy chain type)

               -  Serum free light chain (FLC) ≥10 mg/dL with abnormal ratio

          -  ≥1 bone lesion identifiable by radiograph, computed tomography, positron emission
             tomography - computed tomography (PET CT), or magnetic resonance imaging (MRI)

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2

          -  Adequate hepatic function, with bilirubin ≤1.5 x upper limit of normal (ULN), and
             aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 x ULN

          -  Absolute neutrophil count (ANC) ≥1.5 × 10e9/L, hemoglobin (Hb) ≥9.0 g/dL, and platelet
             count ≥75.0 × 10e9/L independent of transfusion of red blood cells (RBC) or platelet
             concentrates and independent of granulocyte colony stimulating factor (G-CSF) or
             granulocyte macrophage colony stimulating factor (GM-CSF)

          -  International normalized ratio (INR) ≤ 1.5 and partial thromboplastin time (PTT) ≤ 1.5
             x ULN. PT can be used instead of INR if ≤ 1.5 x ULN

        Exclusion Criteria:

          -  Systemic glucocorticoid therapy (prednisone &gt;10 mg/day orally or equivalent) within
             the last 4 weeks prior to first dose, unless tapered and on a stable dose (prednisone
             ≤10 mg/day orally or equivalent) for at least 1 week

          -  Subjects with known POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy,
             monoclonal protein, and skin changes) or light chain (AL) amyloidosis

          -  Plasma cell leukemia

          -  Subject has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic
             half-lives of the treatment, whichever is longer, before the date of randomization. A
             list of anti-myeloma treatments with the corresponding pharmacokinetic half-lives is
             provided in the Site Investigational Product Procedures Manual (IPPM).

          -  Radiation therapy in the previous 4 weeks prior to first dose except if given for pain
             management and involves less than 10% of the bone marrow

          -  Prior treatment with radium-223 dichloride or any experimental radiopharmaceutical

          -  Congestive heart failure (New York Heart Association [NYHA] class III to IV),
             symptomatic cardiac ischemia, cardiomyopathy, clinically relevant ventricular
             arrhythmia, pericardial disease, unstable angina or myocardial infarct in the previous
             6 months prior to first dose, left ventricular ejection fraction &lt;40%

          -  Neuropathy ≥ Grade 2 or Grade 1 with pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-84 22937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Oncology/Hematology Associates</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3729</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-4417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggido</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ciutat Sanitària i Universitaria de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2016</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radium-223 dichloride</keyword>
  <keyword>bortezomib</keyword>
  <keyword>dexamethasone</keyword>
  <keyword>early relapsed multiple myeloma</keyword>
  <keyword>combination therapy multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

